A Randomized, Double-blind, Multicenter Phase III Clinical Study to Evaluate the Efficacy and Safety of Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant Versus Placebo Combined With Fulvestrant in HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer Patients After Prior CDK4/6 Inhibitor Treatment
Latest Information Update: 22 Apr 2025
At a glance
- Drugs Fulvestrant (Primary) ; Sirolimus (Primary)
- Indications HER2 negative breast cancer; Male breast cancer
- Focus Registrational; Therapeutic Use
- Sponsors CSPC ZhongQi Pharmaceutical Technology
Most Recent Events
- 22 Apr 2025 New trial record